Adlai Nortye announces first dose and FDA IND clearance for AN4035
Adlai Nortye said it dosed its first patient in Australia and received U.S. FDA IND clearance for AN4035, a pan-RAS(ON) inhibitor-based ADC.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.